4 papers indexed here
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Aims: Fifty percent of patients with metastatic renal cell carcinoma (RCC) die within the first year. Therefore, survival in the first-line setting is of paramount importance. Cabozantinib has been introduced for use in the first-line setting. We plan to conduct a study on its contribution to survival in Turkiye's popu...
Background/Objectives: Therapeutic options for metastatic breast cancer vary according to hormone receptor (HR) status, human epidermal growth factor receptor 2 (HER2) status, and, importantly, the newly recognized HER2-low status. In triple-negative breast cancer (TNBC), characterized by the absence of HR and HER2 rec...
In this two-center retrospective cohort, nivolumab was associated with longer PFS and OS than axitinib in the second-line treatment of mRCC, and these associations remained significant after adjustment for IMDC risk group and year of treatment initiation.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
